Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.
Grace Baek, PharmD, BCOP
Advertisement
Articles by Grace Baek, PharmD, BCOP
This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.
Opportunities for further optimization of CML management remain.
New agents can offer a more tailored approach to therapy selection.
Melanoma is responsible for 80% of skin cancer deaths.
New therapeutics for prostate cancer must continue to be assessed for comparative safety and efficacy, as well as accessibility for patients.
Advertisement
Latest Updated Articles
Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant SettingPublished: October 11th 2022 | Updated:
Navigating Drug Resistance in Chronic Myelocytic LeukemiaPublished: October 13th 2022 | Updated:
Pirtobrutinib and BTK Inhibitors in the CLL Treatment LandscapePublished: April 17th 2024 | Updated:
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2Published: October 16th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Hormone Therapy Use, Understanding, and Perceptions Have Positively Shifted From 2021 to 2025
5
